Yaoyanshe

About Yaoyanshe

Yaoyanshe, operating under Shanghai Miaoyi Biotechnology Co., Ltd., is a technology-driven Contract Research Organization (CRO) established in December 2015. The company was founded by CEO Sun Meilin, whose background as a clinical doctor at a top-tier hospital and later as a vice president at a CRO and Pfizer, provided her with a comprehensive understanding of the pain points in clinical research. This experience shaped the company's mission to enhance the efficiency of pharmaceutical research and development.

The firm provides a technology-centric platform that digitizes and streamlines the clinical trial process for pharmaceutical companies, biotech firms, and medical device manufacturers. Its business model revolves around a core strategy described as "one body, two wings": using an innovative talent supply model as its body, with data empowerment and technology as its wings. Yaoyanshe generates revenue by offering a suite of services aimed at reducing R&D costs and accelerating development timelines, claiming to shorten cycles by 20% and lower costs by 15%. Its clientele includes over 200 domestic and international pharmaceutical companies and medical institutions.

The company's service portfolio is extensive, covering traditional CRO services like clinical monitoring and project management, alongside Site Management Organization (SMO) services, which include on-site management and patient recruitment. Yaoyanshe also offers a Functional Service Provider (FSP) model for talent outsourcing, site start-up (SSU) services, and intelligent data services. A key component of its offering is a suite of proprietary digital products, including the "Trial.Link" platform, which connects sponsors, hospitals, researchers, and patients, and the "Yaoyanshe App," a community and tool hub for clinical research professionals. The company has received significant backing from prominent investors such as Sequoia Capital, Matrix Partners China, GGV Capital, and others over multiple funding rounds.